The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Distinct structural classes of activating FOXA1 alterations in advanced prostate cancer
Open accessAbstract
Abtract Forkhead box A1 (FOXA1) is a pioneer transcription factor that is essential for the normal development of several endoderm-derived organs, including the prostate gland 1,2. FOXA1 is frequently mutated in hormone-receptor-driven prostate, breast, bladder and salivary-gland tumours 3-8. However, it is unclear how FOXA1 alterations affect the development of cancer, and FOXA1 has previously been ascribed both tumour-suppressive 9-11 and oncogenic 12-14 roles. Here we assemble an aggregate cohort of 1,546 prostate cancers and show that FOXA1 alterations fall into three structural classes that diverge in clinical incidence and genetic co-alteration profiles, with a collective prevalence of 35%. Class-1 activating mutations originate in early prostate cancer without alterations in ETS or SPOP, selectively recur within the wing-2 region of the DNA-binding forkhead domain, enable enhanced chromatin mobility and binding frequency, and strongly transactivate a luminal androgen-receptor program of prostate oncogenesis. By contrast, class-2 activating mutations are acquired in metastatic prostate cancers, truncate the C-terminal domain of FOXA1, enable dominant chromatin binding by increasing DNA affinity and-through TLE3 inactivation-promote metastasis driven by the WNT pathway. Finally, class-3 genomic rearrangements are enriched in metastatic prostate cancers, consist of duplications and translocations within the FOXA1 locus, and structurally reposition a conserved regulatory element-herein denoted FOXA1 mastermind (FOXMIND)-to drive overexpression of FOXA1 or other oncogenes. Our study reaffirms the central role of FOXA1 in mediating oncogenesis driven by the androgen receptor, and provides mechanistic insights into how the classes of FOXA1 alteration promote the initiation and/or metastatic progression of prostate cancer. These results have direct implications for understanding the pathobiology of other hormone-receptor-driven cancers and rationalize the co-targeting of FOXA1 activity in therapeutic strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“many key genes that drive PCa, such as FOXA1 or HOXB13 (refs. 7,8), promote tumor progression by regulating how AR binds to or activates its target genes.”
From Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer (2025) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Heinz, S., Benner, C., Spann, N., Bertolino, E., Lin, Y. C., Laslo, P., Cheng, J. X., Murre, C., Singh, H., & Glass, C. K. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.05.004 · Cited by 13,382
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
MEME SUITE: tools for motif discovery and searching
Bailey, T. L., Boden, M., Buske, F. A., Frith, M., Grant, C. E., Clementi, L., Ren, J., Li, W. W., & Noble, W. S. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp335 · Cited by 10,648
deepTools2: a next generation web server for deep-sequencing data analysis
Ramírez, F., Ryan, D. P., Grüning, B., Bhardwaj, V., Kilpert, F., Richter, A. S., Heyne, S., Dündar, F., & Manke, T. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw257 · Cited by 8,096
Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y., & Greenleaf, W. J. (2013) · Nature Methods · doi:10.1038/nmeth.2688 · Cited by 6,422
voom: precision weights unlock linear model analysis tools for RNA-seq read counts
Law, C. W., Chen, Y., Shi, W., & Smyth, G. K. (2014) · Genome Biology · doi:10.1186/gb-2014-15-2-r29 · Cited by 6,155
Research works printed but not linked: 1
- Smyth, G. K., McCarthy, D. J. & Smyth, G. K. in Bioinformatics and Computational Biology Solutions Using R and Bioconductor (eds Dudoit, S. & Carey, V. J.) 397–420 (Springer, New York, 2005).
Cited by
Sorted by citations
Rebello, R. J., Oing, C., Knudsen, K. E., Loeb, S., Johnson, D. C., Reiter, R. E., Gillessen, S., van der Kwast, T., & Bristow, R. G. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00243-0 · Cited by 1,238
Pioneer Transcription Factors Initiating Gene Network Changes
Zaret, K. S. (2020) · Annual Review of Genetics · doi:10.1146/annurev-genet-030220-015007 · Cited by 409
A genomic and epigenomic atlas of prostate cancer in Asian populations
Li, J., Xu, C., Lee, H. J., Ren, S., Zi, X., Zhang, Z., Wang, H., Yu, Y., Yang, C., Gao, X., et al. (2020) · Nature · doi:10.1038/s41586-020-2135-x · Cited by 353
Self-citationTargeting SWI/SNF ATPases in enhancer-addicted prostate cancer
Xiao, L., Parolia, A., Qiao, Y., Bawa, P., Eyunni, S., Mannan, R., Carson, S. E., Chang, Y., Wang, X., Zhang, Y., et al. (2021) · Nature · doi:10.1038/s41586-021-04246-z · Cited by 324
Self-citationEpidemiology and genomics of prostate cancer in Asian men
Zhu, Y., Mo, M., Yu, W., Wu, J., Pan, J. G., Freedland, S. J., Zheng, Y., & Ye, D. (2021) · Nature Reviews Urology · doi:10.1038/s41585-021-00442-8 · Cited by 293
Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
Tang, F., Xu, D., Wang, S., Wong, C. K., Martinez‐Fundichely, A., Lee, C. J., Cohen, S. M., Park, J., Hill, C. E., Eng, K. W., et al. (2022) · Science · doi:10.1126/science.abe1505 · Cited by 272
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials
He, Y., Xu, W., Xiao, Y., Huang, H., Gu, D., & Ren, S. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01042-7 · Cited by 287
SOX4: The unappreciated oncogene
Moreno, C. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.08.027 · Cited by 227
Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
Feng, Q. F., & He, B. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00858 · Cited by 202
Pioneer of prostate cancer: past, present and the future of FOXA1
Teng, M., Zhou, S., Cai, C., Lupien, M., & He, H. H. (2020) · Protein & Cell · doi:10.1007/s13238-020-00786-8 · Cited by 180
Fu, X., Pereira, R., Angelis, C. D., Veeraraghavan, J., Nanda, S., Qin, L., Cataldo, M. L., Sethunath, V., Mehravaran, S., Gutiérrez, C., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1911584116 · Cited by 167
FOXA2 drives lineage plasticity and KIT pathway activation in neuroendocrine prostate cancer
Han, M., Li, F., Zhang, Y., Dai, P., He, J., Li, Y., Zhu, Y., Zheng, J., Huang, H., Bai, F., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.011 · Cited by 166
Self-citationTargeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2
Qiao, Y., Wang, X., Mannan, R., Pitchiaya, S., Zhang, Y., Wotring, J. W., Xiao, L., Robinson, D. R., Wu, Y., Tien, J. C.-Y., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2021450118 · Cited by 166
Self-citationCheng, Q., Butler, W., Zhou, Y., Zhang, H., Tang, L., Perkinson, K., Chen, X., Jiang, X. “., McCall, S. J., Inman, B. A., et al. (2022) · European Urology · doi:10.1016/j.eururo.2021.12.039 · Cited by 165
Reprogramming of the FOXA1 cistrome in treatment-emergent neuroendocrine prostate cancer
Baca, S. C., Takeda, D. Y., Seo, J.-H., Hwang, J. H., Ku, S., Arafeh, R., Arnoff, T. E., Agarwal, S., Bell, C. A., O’Connor, E. P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22139-7 · Cited by 163
Wang, X., Xu, J., Zhang, B., Hou, Y., Song, F., Lyu, H., & Yue, F. (2021) · Nature Methods · doi:10.1038/s41592-021-01164-w · Cited by 152
Self-citationCellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications
Testa, U., Castelli, G., & Pelosi, E. (2019) · Medicines · doi:10.3390/medicines6030082 · Cited by 168
Pioneer factors: roles and their regulation in development
Barral, A., & Zaret, K. S. (2023) · Trends in Genetics · doi:10.1016/j.tig.2023.10.007 · Cited by 135
Arruabarrena-Aristorena, A., Maag, J. L. V., Kittane, S., Cai, Y., Karthaus, W. R., Ladewig, E., Park, J., Kannan, S., Ferrando, L., Cocco, E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.003 · Cited by 130
Chromatin binding of FOXA1 is promoted by LSD1-mediated demethylation in prostate cancer
Gao, S., Chen, S., Han, D. G., Wang, Z., Li, M., Han, W., Besschetnova, A., Liu, M., Zhou, F., Barrett, D. A., et al. (2020) · Nature Genetics · doi:10.1038/s41588-020-0681-7 · Cited by 132
Wang, R., Yamada, T., Kita, K., Taniguchi, H., Arai, S., Fukuda, K., Terashima, M., Ishimura, A., Nishiyama, A., Tanimoto, A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18442-4 · Cited by 116
Self-citationLowder, D., Rizwan, K., McColl, C., Paparella, A. T., Ittmann, M., Mitsiades, N., & Kaochar, S. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.01.028 · Cited by 118
ARe we there yet? Understanding androgen receptor signaling in breast cancer
Michmerhuizen, A. R., Spratt, D. E., Pierce, L. J., & Speers, C. W. (2020) · npj Breast Cancer · doi:10.1038/s41523-020-00190-9 · Cited by 111
Prostate cancer treatment – China's perspective
Liu, J., Dong, L., Zhu, Y., Dong, B., Sha, J., Zhu, H. H., Pan, J., & Xue, W. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215927 · Cited by 107
The epigenetic and transcriptional landscape of neuroendocrine prostate cancer
Davies, A., Zoubeidi, A., & Selth, L. A. (2019) · Endocrine Related Cancer · doi:10.1530/erc-19-0420 · Cited by 100
Skala, S. L., Wang, X., Zhang, Y., Mannan, R., Wang, L., Narayanan, S. P., Vats, P., Su, F., Chen, J., Cao, X., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.03.003 · Cited by 96
Self-citationFOXA1 overexpression suppresses interferon signaling and immune response in cancer
He, Y., Wang, L., Wei, T., Xiao, Y., Sheng, H., Su, H., Hollern, D. P., Zhang, X., Ma, J., Wen, S., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci147025 · Cited by 96
Hazafa, A., Mumtaz, M., Farooq, M. F., Bilal, S., Chaudhry, S. N., Firdous, M., Naeem, H., Ullah, M. O., Yameen, M., Mukhtiar, M., et al. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118525 · Cited by 98
Illuminating the noncoding genome in cancer
Zhang, X., & Meyerson, M. M. (2020) · Nature Cancer · doi:10.1038/s43018-020-00114-3 · Cited by 86
Igarashi, K., Nishizawa, H., Saiki, Y., & Matsumoto, M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101032 · Cited by 89
Modulating Androgen Receptor-Driven Transcription in Prostate Cancer with Selective CDK9 Inhibitors
Richters, A., Doyle, S. K., Freeman, D. B., Lee, C., Leifer, B. S., Jagannathan, S., Kabinger, F., Koren, J. V., Struntz, N. B., Urgiles, J., et al. (2021) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.10.001 · Cited by 86
Linder, S., Hoogstraat, M., Stelloo, S., Eickhoff, N., Schuurman, K. G., de Barros, H. A., Alkemade, M., Bekers, E. M., Severson, T., Sanders, J., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0576 · Cited by 83
Self-citationMolecular mechanisms underlying the development of neuroendocrine prostate cancer
Liu, S., Alabi, B. R., Yin, Q., & Stoyanova, T. I. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.007 · Cited by 84
Shaping Chromatin States in Prostate Cancer by Pioneer Transcription Factors
Hankey, W., Chen, Z., & Wang, Q. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3447 · Cited by 86
Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
Ehsani, M., David, F. O., & Baniahmad, A. (2021) · Cancers · doi:10.3390/cancers13071534 · Cited by 83
STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity
Zhou, J., Tison, K., Zhou, H., Bai, L., Acharyya, R. K., McEachern, D., Metwally, H., Wang, Y., Pitter, M. R., Choi, J. E., et al. (2025) · Nature · doi:10.1038/s41586-025-09000-3 · Cited by 88
Self-citationChen, C.-C., Tran, W., Song, K., Sugimoto, T., Obusan, M. B., Wang, L., Sheu, K. M., Cheng, D., Ta, L. H., Varuzhanyan, G., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.10.009 · Cited by 77
FOXA1 and FOXA2: the regulatory mechanisms and therapeutic implications in cancer
Liu, N., Wang, A., Xue, M., Zhu, X., Liu, Y., & Chen, M. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-01936-1 · Cited by 83
Park, S. H., Fong, K.-W., Kim, J., Wang, F., Lü, X., Lee, Y., Brea, L. T., Wadosky, K. M., Guo, C., Abdulkadir, S. A., et al. (2021) · Science Advances · doi:10.1126/sciadv.abe2261 · Cited by 78
Wang, T.-Y., Liu, Q., Ren, Y., Alam, S. K., Wang, L., Zhu, Z., Hoeppner, L. H., Dehm, S. M., Cao, Q., & Yang, R. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.028 · Cited by 77
Noncoding mutations target cis-regulatory elements of the FOXA1 plexus in prostate cancer
Zhou, S., Hawley, J. R., Soares, F., Grillo, G., Teng, M., Tonekaboni, S. A. M., Hua, J. T., Kron, K. J., Mazrooei, P., Ahmed, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14318-9 · Cited by 69
The 5-Hydroxymethylcytosine Landscape of Prostate Cancer
Sjöström, M., Zhao, S. G., Levy, S., Zhang, M., Ning, Y., Shrestha, R., Lundberg, A., Herberts, C., Foye, A., Aggarwal, R. R., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-22-1123 · Cited by 72
Self-citationPioneering the developmental frontier
Larson, E. D., Marsh, A. J., & Harrison, M. M. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.02.020 · Cited by 64
Li, Q., Ren, Z., Cao, K., Li, M. M., Wang, K., & Zhou, Y. (2022) · Science Advances · doi:10.1126/sciadv.abj1624 · Cited by 66
FOXA1: A Pioneer of Nuclear Receptor Action in Breast Cancer
Seachrist, D. D., Anstine, L. J., & Keri, R. (2021) · Cancers · doi:10.3390/cancers13205205 · Cited by 68
Dai, S., Qu, L., Li, J., & Chen, Y. (2021) · Nucleic Acids Research · doi:10.1093/nar/gkab807 · Cited by 63
Assigning functionality to cysteines by base editing of cancer dependency genes
Li, H., Ma, T., Remsberg, J. R., Won, S. J., DeMeester, K. E., Njomen, E., Ogasawara, D., Zhao, K. T., Huang, T. P., Lu, B., et al. (2023) · Nature Chemical Biology · doi:10.1038/s41589-023-01428-w · Cited by 62
Zhang, Y., Ming, A., Wang, J., Chen, W., & Fang, Z. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107234 · Cited by 65
Self-citationPatel, S. A., Rodrigues, P., Wesolowski, L., & Vanharanta, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01127-6 · Cited by 57
Stopsack, K. H., Nandakumar, S., Arora, K. S., Nguyen, B., Vasselman, S. E., Nweji, B., McBride, S. M., Morris, M. J., Rathkopf, D. E., Slovin, S. F., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2577 · Cited by 60
Li, X., Wang, Y., Deng, S., Zhu, G., Wang, C., Johnson, N. A., Zhang, Z., Tirado, C. R., Xu, Y., Metang, L. A., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.06.010 · Cited by 61
Genome-wide crosstalk between steroid receptors in breast and prostate cancers
Paakinaho, V., & Palvimo, J. (2021) · Endocrine-Related Cancer · doi:10.1530/erc-21-0038 · Cited by 35
FOXA2 rewires AP-1 for transcriptional reprogramming and lineage plasticity in prostate cancer
Wang, Z., Townley, S. L., Zhang, S., Liu, M., Li, M., Labaf, M., Patalano, S. C., Venkataramani, K., Siegfried, K. R., Macoska, J. A., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-49234-9 · Cited by 51
Grbeša, I., Augello, M. A., Liu, D., McNally, D. R., Gaffney, C., Huang, D., Lin, K., Ivenitsky, D., Goueli, R. S., Robinson, B. D., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109625 · Cited by 47
Tewari, A. K., Cheung, A. T. M., Crowdis, J. P., Conway, J. R., Camp, S. Y., Wankowicz, S. A. M., Livitz, D. G., Park, J., Lis, R. T., Bosma-Moody, A., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109665 · Cited by 47
Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies
Yang, J., Zhou, F., Luo, X., Fang, Y., Wang, X., Liu, X., Xiao, R., Jiang, D., Tang, Y., Yang, G., et al. (2025) · Cell Death Discovery · doi:10.1038/s41420-025-02366-3 · Cited by 56
Self-citationERG orchestrates chromatin interactions to drive prostate cell fate reprogramming
Li, F., Yuan, Q., Di, W., Xia, X., Liu, Z., Mao, N., Li, L., Li, C., He, J., Li, Y., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137967 · Cited by 47
Redirecting the pioneering function of FOXA1 with covalent small molecules
Won, S. J., Zhang, Y., Reinhardt, C. J., Hargis, L. M., MacRae, N. S., DeMeester, K. E., Njomen, E., Remsberg, J. R., Melillo, B. N., Cravatt, B. F., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.09.024 · Cited by 43
Self-citationWarrick, J. I., Hu, W., Yamashita, H., Walter, V., Shuman, L., Craig, J. M., Gellert, L. L., Castro, M. A. A., Robertson, A. G., Kuo, F., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-34251-3 · Cited by 44
Zhao, S. G., Bootsma, M., Zhou, S., Shrestha, R., Moreno-Rodriguez, T., Lundberg, A., Pan, C., Arlidge, C., Hawley, J. R., Foye, A., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01826-3 · Cited by 42
Self-citationTranscription Factors: The Fulcrum Between Cell Development and Carcinogenesis
Islam, Z., Ali, A. M., Naik, A., Eldaw, M., Decock, J. V., & Kolatkar, P. R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.681377 · Cited by 46
Kish, E. K., Choudhry, M., Gamallat, Y., Buharideen, S. M., Dhananjaya, D. K. G., & Bismar, T. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094772 · Cited by 42
NSD2 is a requisite subunit of the AR/FOXA1 neo-enhanceosome in promoting prostate tumorigenesis
Parolia, A., Eyunni, S., Verma, B. K., Young, E., Liu, Y., Liu, L., George, J. M., Aras, S., Das, C. K., Mannan, R., et al. (2024) · Nature Genetics · doi:10.1038/s41588-024-01893-6 · Cited by 40
Self-citationDarolutamide antagonizes androgen signaling by blocking enhancer and super‐enhancer activation
Baumgart, S. J., Nevedomskaya, E., Lesche, R., Newman, R., Mumberg, D., & Haendler, B. (2020) · Molecular Oncology · doi:10.1002/1878-0261.12693 · Cited by 42
Feng, T., Zhao, R., Sun, F., Lu, Q., Wang, X., Hu, J., Wang, S., Gao, L., Zhou, Q., Xiong, X., et al. (2019) · Oncogene · doi:10.1038/s41388-019-0991-3 · Cited by 39
Self-citationBao, Y., Qiao, Y., Choi, J. E., Zhang, Y., Mannan, R., Cheng, C., He, T., Zheng, Y., Yu, J., Gondal, M. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314416120 · Cited by 39
Self-citationMutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment
Filipska, M., & Rosell, R. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12983 · Cited by 38
Berchuck, J. E., Adib, E., Alaiwi, S. A., Dash, A. K., Shin, J. N., Lowder, D., McColl, C., Castro, P. D., Carelli, R., Benedetti, E., et al. (2022) · Cancer Research · doi:10.1158/0008-5472.can-21-3552 · Cited by 38
FOXA1 regulates alternative splicing in prostate cancer
Giudice, M. D., Foster, J. G., Peirone, S., Rissone, A., Caizzi, L., Gaudino, F., Parlato, C., Anselmi, F., Arkell, R., Guarrera, S., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.111404 · Cited by 41
Giafaglione, J. M., Crowell, P. D., Delcourt, A. M. L., Hashimoto, T., Ha, S. M., Atmakuri, A., Nunley, N. M., Dang, R. M. A., Tian, M., Diaz, J. A., et al. (2023) · Nature Cell Biology · doi:10.1038/s41556-023-01274-x · Cited by 40
Grishin, D., & Gusev, A. (2022) · Nature Genetics · doi:10.1038/s41588-022-01075-2 · Cited by 35
Biological and Clinical Aspects of Metastatic Spinal Tumors
Litak, J., Czyżewski, W., Szymoniuk, M., Sakwa, L., Pasierb, B., Litak, J., Hoffman, Z., Kamieniak, P., & Roliński, J. (2022) · Cancers · doi:10.3390/cancers14194599 · Cited by 39
Wang, Y., Zhang, L., Wei, N., Sun, Y., Pan, W., & Chen, Y. (2020) · Aging · doi:10.18632/aging.202247 · Cited by 36
Race and prostate cancer: genomic landscape
Gallo, C. A., Owiredu, J. N., Weinstein, I., Lewicki, P., Basourakos, S. P., Vince, R., Awamlh, B. A. H. A., Schumacher, F. R., Spratt, D. E., Barbieri, C. E., et al. (2022) · Nature Reviews Urology · doi:10.1038/s41585-022-00622-0 · Cited by 36
Lerner, J., Katznelson, A., Zhang, J., & Zaret, K. S. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112748 · Cited by 37
ACK1–AR and AR–HOXB13 signaling axes: epigenetic regulation of lethal prostate cancers
Kim, E. H., Cao, D., Mahajan, N. P., Andriole, G. L., & Mahajan, K. N. (2020) · NAR Cancer · doi:10.1093/narcan/zcaa018 · Cited by 37
Targeting histone H2B acetylated enhanceosomes via p300/CBP degradation in prostate cancer
Luo, J., Chen, Z., Qiao, Y., Tien, J. C.-Y., Young, E., Mannan, R., Mahapatra, S., Bhattacharyya, R., Xiao, L., He, T., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02336-6 · Cited by 39
Self-citationMalinczak, C., Parolia, A., Fonseca, W., Morris, S. B., Rasky, A. J., Bawa, P., Zhang, Y., Mire, M. M., Ziegler, S. F., Ptaschinski, C., et al. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2001205 · Cited by 35
Self-citationMather, R. L., Parolia, A., Carson, S. E., Venalainen, E., Roig-Carles, D., Jaber, M., Chu, S., Alborelli, I., Wu, R. C., Lin, D., et al. (2021) · Molecular Oncology · doi:10.1002/1878-0261.12954 · Cited by 34
Self-citationSahoo, S. S., Ramanand, S. G., Gao, Y., Abbas, A., Kumar, A., Cuevas, I., Li, H., Aguilar, M., Xing, C., Mani, R. S., et al. (2022) · Journal of Clinical Investigation · doi:10.1172/jci157574 · Cited by 32
Dong, H., Ding, L., Zhou, T.-R., Yan, T., Li, J., & Liang, C. (2022) · Asian Journal of Andrology · doi:10.4103/aja202259 · Cited by 33
Mortenson, K. L., Dawes, C., Wilson, E. R., Patchen, N. E., Johnson, H. E., Gertz, J., Bailey, S. D., Yang, J., Varley, K. E., & Zhang, X. (2024) · Nature Communications · doi:10.1038/s41467-024-50387-w · Cited by 35
Yue, M., Yun, Z., Li, S., Yan, G., & Kang, Z. (2021) · RNA Biology · doi:10.1080/15476286.2021.1885232 · Cited by 32
Molecular Mechanisms of Oncogenesis through the Lens of Nucleosomes and Histones
Espiritu, D., Gribkova, A. K., Gupta, S., Shaytan, A. К., & Panchenko, A. R. (2021) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.1c00694 · Cited by 31
Hybrid Oncocytic Tumors (HOTs) in Birt-Hogg-Dubé Syndrome Patients—A Tale of Two Cities
Wang, X., Mannan, R., Zhang, Y., Chinnaiyan, A. K., Rangaswamy, R., Chugh, S., Su, F., Cao, X., Wang, R., Skala, S. L., et al. (2023) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000002152 · Cited by 31
Self-citationDong, B., Xu, J., Huang, Y., Guo, J., Dong, Q., Wang, Y., Li, N., Liu, Q., Zhang, M., Pan‐Hammarström, Q., et al. (2024) · Nature Cancer · doi:10.1038/s43018-024-00820-2 · Cited by 33
Bajo-Santos, C., Brokāne, A., Zayakin, P., Endzeliņš, E., Soboļevska, K., Belovs, A., Jansons, J., Sperga, M., Llorente, A., Radoviča-Spalviņa, I., et al. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.980433 · Cited by 31
Three-dimensional genome landscape of primary human cancers
Yost, K. E., Zhao, Y., Hung, K. L., Zhu, K., Xu, D., Corces, M. R., Shams, S., Louie, B. H., Sarmashghi, S., Sundaram, L., et al. (2025) · Nature Genetics · doi:10.1038/s41588-025-02188-0 · Cited by 34
Newman, J. A., Aitkenhead, H., Gavard, A. E., Rota, I. A., Handel, A. E., Holländer, G. A., & Gileadi, O. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.010365 · Cited by 28
Emerging roles of long noncoding RNAs in cholangiocarcinoma: Advances and challenges
Yang, Y., Deng, X., Li, Q., Wang, F., Miao, L., & Jiang, Q. (2020) · 癌症：英文版 · doi:10.1002/cac2.12109 · Cited by 26
Gene Fusions Create Partner and Collateral Dependencies Essential to Cancer Cell Survival
Gillani, R., Seong, B. K. A., Crowdis, J. P., Conway, J. R., Dharia, N. V., Alimohamed, S. I., Haas, B. J., Han, K., Park, J., Dietlein, F., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-0791 · Cited by 28
Neyret‐Kahn, H., Fontugne, J., Meng, X. Y., Groeneveld, C. S., Cabel, L., Ye, T., Guyon, E., Krucker, C., Dufour, F., Chapeaublanc, E., et al. (2023) · Oncogene · doi:10.1038/s41388-023-02662-1 · Cited by 27
Fu, X., Pereira, R., Liu, C.-C., Angelis, C. D., Shea, M. J., Nanda, S., Qin, L., Mitchell, T., Cataldo, M. L., Veeraraghavan, J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112821 · Cited by 26
Derivation and Application of Molecular Signatures to Prostate Cancer: Opportunities and Challenges
Doultsinos, D., & Mills, I. G. (2021) · Cancers · doi:10.3390/cancers13030495 · Cited by 25
Hwang, J. H., Arafeh, R., Seo, J.-H., Baca, S. C., Ludwig, M., Arnoff, T. E., Sawyer, L., Richter, C., Tape, S., Bergom, H. E., et al. (2022) · eLife · doi:10.7554/elife.73223 · Cited by 26
DNA-PK, Nuclear mTOR, and the Androgen Pathway in Prostate Cancer
Giguère, V. (2020) · Trends in cancer · doi:10.1016/j.trecan.2020.01.015 · Cited by 25
BARTweb: a web server for transcriptional regulator association analysis
Ma, W., Wang, Z., Zhang, Y., Magee, N. E., Feng, Y., Shi, R., Chen, Y., & Zang, C. (2021) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqab022 · Cited by 25
Self-citationDivergent FOXA1 mutations drive prostate tumorigenesis and therapy-resistant cellular plasticity
Eyunni, S., Mannan, R., Zhang, Y., Young, E., Zhang, Q., Luo, J., Pang, M., Mahapatra, S., Tien, J. C.-Y., George, J. M., et al. (2025) · Science · doi:10.1126/science.adv2367 · Cited by 30
Self-citationThe Sly Oncogene: FOXA1 Mutations in Prostate Cancer
Shah, N., & Brown, M. A. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.07.005 · Cited by 24
Cyrta, J., Prandi, D., Arora, A., Hovelson, D. H., Sboner, A., Rodrı́guez, A., Fedrizzi, T., Beltran, H., Robinson, D. R., Gopalan, A., et al. (2022) · The Journal of Pathology · doi:10.1002/path.5887 · Cited by 24
Self-citation
Metadata
- Authors
- Parolia, A., Cieslik, M., Chu, S.-C., Xiao, L., Ouchi, T., Zhang, Y., Wang, X., Vats, P., Cao, X., Pitchiaya, S., Su, F., Wang, R., Feng, F. Y., Wu, Y.-M., Lonigro, R. J., Robinson, D. R., & Chinnaiyan, A. M.
- Affiliations
- University of Michigan (US)
- Howard Hughes Medical Institute (US)
- University of California, San Francisco (US)
- Corresponding author
- Chinnaiyan, Arul M.
- ORCID
- Venue
- Nature
- Published
- 2019-06-26
- Volume
- 571
- Issue
- 7765
- Pages
- 413-418
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC6661908
- OpenAlex
- W2955719861
- Cited by
- 284
- References
- 60
- Citations by year
- 2026: 25 · 2025: 40 · 2024: 34 · 2023: 44 · 2022: 47 · 2021: 50 · 2020: 35 · 2019: 9
- FWCI
- 25.92
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Cancer Institute (F99CA245825, R35CA231996, U01CA214170, P50CA186786)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- FOXA1, prostate cancer, activating mutations, androgen receptor, chromatin binding, metastasis, Wnt signaling, TLE3, genome rearrangement, ETS transcription factors, SPOP, carcinogenesis
- MeSH terms
- Protein Domains, Chromatin, Humans, Male, Models, Molecular, Mutation, Neoplasm Metastasis, Prostatic Neoplasms, Receptors, Androgen, Genome, Human, Gene Expression Regulation, Neoplastic, Cell Line, Tumor, Hepatocyte Nuclear Factor 3-alpha, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
